Particle Sciences has completed the clinical trial manufacture of vaginal rings under development for HIV prevention that are designed to deliver the pro-drug tenofovir disoproxil fumarate for 30 days. In studies conducted at the Center for Disease Control, the ring provided complete protection against the related virus, SHIV. The product is a drug-eluting device funded under an NIH grant led by Betsy Herold, M.D., Professor and Director, Translational Prevention Research Center at Albert Einste...